-
公开(公告)号：US20120135430A1
公开(公告)日：2012-05-31
申请号：US13321522
申请日：2010-05-21
IPC分类号： G01N33/577 , G01N33/566
CPC分类号： G01N33/566 , C07K16/18 , G01N33/564 , G01N33/6893 , G01N2333/4716 , G01N2800/16 , G01N2800/164 , G01N2800/50 , G01N2800/52 , G01N2800/7042
摘要： The present invention provides methods for assessing complement activation and methods for assessing the ability of an agent or condition of interest to modulate complement activation. The present invention provides methods for assessing whether a subject has or is at increased risk of developing a complement-mediated disorder, e.g., age-related macular degeneration (AMD). Also provided are kits containing materials useful for performing the methods.
摘要翻译： 本发明提供了用于评估补体活化的方法和评估感兴趣的药剂或病症调节补体活化能力的方法。 本发明提供用于评估受试者是否具有发生补体介导的病症（例如年龄相关性黄斑变性（AMD））的风险增加的方法。 还提供了包含用于执行方法的材料的试剂盒。
-
公开(公告)号：US20110182877A1
公开(公告)日：2011-07-28
申请号：US12681392
申请日：2008-10-02
申请人： Cedric Francois , Pascal Deschatelets , Paul Olson
发明人： Cedric Francois , Pascal Deschatelets , Paul Olson
IPC分类号： A61K38/08 , A61K39/395 , A61K38/10 , A61P27/02
CPC分类号： A61K9/0051 , A61K38/12 , A61K47/42
摘要： The present invention features the sustained delivery of compstatin analog and, optionally, an additional active agent, by release from a macroscopic, gel-like deposit formed by administering a liquid solution containing the compstatin analog to an extravascular location in the body of a mammalian subject such as the vitreous chamber.
摘要翻译： 本发明的特征在于通过从包含化合物抑制物类似物的液体溶液施用于哺乳动物受试者体内的血管外位置形成的宏观的凝胶状沉积物释放，持续递送化合物类似物和任选的另外的活性剂 如玻璃体腔。
-
公开(公告)号：US20070238654A1
公开(公告)日：2007-10-11
申请号：US11544389
申请日：2006-10-06
申请人： Pascal Deschatelets , Paul Olson , Cedric Francois
发明人： Pascal Deschatelets , Paul Olson , Cedric Francois
CPC分类号： C07K7/08 , A61F9/0008 , A61K9/0019 , A61K9/0048 , A61K9/0051 , A61K31/00 , A61K31/7105 , A61K38/00 , A61K38/08 , A61K38/10 , A61K38/12 , A61K38/17 , A61K39/3955 , A61K49/0008 , A61K2039/505 , A61K2039/507 , C07K16/28 , C07K2319/01 , G01N33/6872 , G01N2333/4704 , G01N2500/04 , G01N2500/20
摘要： The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and/or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions.
摘要翻译： 本发明的特征在于使用化合物抑制剂和补体抑制类似物来治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性，脉络膜新生血管形成和/或视网膜新生血管形成的其它病症。 本发明还提供了包含抑制剂或其补体抑制类似物和第二治疗剂的组合物。 本发明还提供了包含抑制抑制剂或其补体抑制类似物和凝胶形成材料例如可溶性胶原蛋白的组合物，以及施用组合物的方法。
-
公开(公告)号：US08043609B2
公开(公告)日：2011-10-25
申请号：US11612751
申请日：2006-12-19
申请人： Pascal Deschatelets , Paul Olson , Cedric Francois
发明人： Pascal Deschatelets , Paul Olson , Cedric Francois
CPC分类号： A61K38/162 , A61K9/0051 , A61K38/17
摘要： The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.
摘要翻译： 本发明提供用于治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性或脉络膜新生血管形成，眼部炎症或其任何组合的其它病症的组合物和方法。 某些组合物包含痘病毒补体对照蛋白或其补体结合片段或变体。 其他组合物包含与结合存在于细胞或非细胞分子实体的表面或其表面上的组分连接的部分的痘病毒补体对照蛋白，例如存在于患有年龄相关性黄斑的风险的患者的眼睛中的组分 变性或相关病症或脉络膜新生血管形成，眼部炎症或这些的任何组合。 某些方法包括向受试者施用痘病毒补体对照蛋白或补体结合片段或其变体。
-
公开(公告)号：US20130296254A1
公开(公告)日：2013-11-07
申请号：US13409941
申请日：2012-03-01
申请人： Pascal Deschatelets , Paul Olson , Cedric Francois
发明人： Pascal Deschatelets , Paul Olson , Cedric Francois
IPC分类号： A61K38/12
CPC分类号： C07K7/08 , A61F9/0008 , A61K9/0019 , A61K9/0048 , A61K9/0051 , A61K31/00 , A61K31/7105 , A61K38/00 , A61K38/08 , A61K38/10 , A61K38/12 , A61K38/17 , A61K39/3955 , A61K49/0008 , A61K2039/505 , A61K2039/507 , C07K16/28 , C07K2319/01 , G01N33/6872 , G01N2333/4704 , G01N2500/04 , G01N2500/20
摘要： The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and/or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions.
摘要翻译： 本发明的特征在于使用化合物抑制剂和补体抑制类似物来治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性，脉络膜新生血管形成和/或视网膜新生血管形成的其它病症。 本发明还提供了包含抑制剂或其补体抑制类似物和第二治疗剂的组合物。 本发明还提供了包含抑制抑制剂或其补体抑制类似物和凝胶形成材料例如可溶性胶原蛋白的组合物，以及施用组合物的方法。
-
公开(公告)号：US20130072442A1
公开(公告)日：2013-03-21
申请号：US13251818
申请日：2011-10-03
申请人： Pascal Deschatelets , Paul Olson , Cedric Francois
发明人： Pascal Deschatelets , Paul Olson , Cedric Francois
IPC分类号： A61K38/16
CPC分类号： A61K38/162 , A61K9/0051 , A61K38/17
摘要： The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.
摘要翻译： 本发明提供用于治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性或脉络膜新生血管形成，眼部炎症或其任何组合的其它病症的组合物和方法。 某些组合物包含痘病毒补体对照蛋白或其补体结合片段或变体。 其他组合物包含与结合存在于细胞或非细胞分子实体的表面或其表面上的组分连接的部分的痘病毒补体对照蛋白，例如存在于患有年龄相关性黄斑的风险的患者的眼睛中的组分 变性或相关病症或脉络膜新生血管形成，眼部炎症或这些的任何组合。 某些方法包括向受试者施用痘病毒补体对照蛋白或补体结合片段或其变体。
-
公开(公告)号：US07947267B2
公开(公告)日：2011-05-24
申请号：US11247886
申请日：2005-10-08
申请人： Cedric Francois , Pascal Deschatelets , Paul Olson
发明人： Cedric Francois , Pascal Deschatelets , Paul Olson
CPC分类号： A61K38/162 , C07K14/005 , C07K2319/33 , C12N2710/24122
摘要： The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.
摘要翻译： 本发明提供用于治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性或脉络膜新生血管形成的其它病症的组合物和方法。 某些组合物包含痘病毒补体对照蛋白或其补体结合片段或变体。 其他组合物包含与结合存在于细胞或非细胞分子实体的表面或其表面上的组分连接的部分的痘病毒补体对照蛋白，例如存在于患有年龄相关性黄斑的风险的患者的眼睛中的组分 变性或相关病症或脉络膜新生血管形成。 某些方法包括向受试者施用痘病毒补体对照蛋白或补体结合片段或其变体。
-
公开(公告)号：US20090220572A1
公开(公告)日：2009-09-03
申请号：US12161410
申请日：2007-01-19
申请人： Pascal Deschatelets , Paul Olson , Cedric Francois
发明人： Pascal Deschatelets , Paul Olson , Cedric Francois
IPC分类号： A61K9/127 , A61K9/00 , A61K39/395 , A61K31/7052 , A61K38/16 , A61K38/02 , A61K38/10 , A61K9/14 , A61P27/02
CPC分类号： C07K7/08 , A61F9/0008 , A61K9/0019 , A61K9/0048 , A61K9/0051 , A61K31/00 , A61K31/7105 , A61K38/00 , A61K38/08 , A61K38/10 , A61K38/12 , A61K38/17 , A61K39/3955 , A61K49/0008 , A61K2039/505 , A61K2039/507 , C07K16/28 , C07K2319/01 , G01N33/6872 , G01N2333/4704 , G01N2500/04 , G01N2500/20
摘要： The present invention provides composition, methods, and articles of manufacture for treating an eye disorder, e.g., a disorder characterized by macular degeneration, choroidal neovascularization, or retinal neovascularization. One method of the invention comprises the step of: administering first and second therapeutic agents to the subject's eye in a single procedure, wherein the first therapeutic agent provides rapid improvement in the condition of the subject's eye and the second therapeutic agent is administered as a sustained release formulation of the second therapeutic agent. For example, the first and second therapeutic agents are administered by intravitreal injection. The first therapeutic agent may be dissolved in a liquid medium located in the syringe and the sustained formulation of the second therapeutic agent may comprise an ocular implant or plurality of particles located in the needle. The therapeutic agents may be selected from the group consisting of angiogenesis inhibitors and complement inhibitors.
摘要翻译： 本发明提供用于治疗眼睛疾病的组合物，方法和制品，例如以黄斑变性，脉络膜新生血管形成或视网膜新生血管形成为特征的病症。 本发明的一种方法包括以下步骤：在单一程序中向受检者的眼睛施用第一和第二治疗剂，其中第一治疗剂提供对象眼睛状况的快速改善，而第二治疗剂作为持续的 释放第二治疗剂的制剂。 例如，第一和第二治疗剂通过玻璃体内注射给药。 第一治疗剂可以溶解在位于注射器中的液体介质中，并且第二治疗剂的持续制剂可以包括眼部植入物或位于针中的多个颗粒。 治疗剂可以选自血管生成抑制剂和补体抑制剂。
-
9.发明授权公开(公告)号：US08198020B2
公开(公告)日：2012-06-12
申请号：US10923940
申请日：2004-08-23
IPC分类号： C12Q1/70 , C12Q1/00 , G01N33/53 , G01N33/567 , G01N33/574
CPC分类号： B82Y5/00 , A61K47/544 , A61K47/62 , A61K47/6911 , A61K47/6913
摘要： The present invention provides a system for enhancing clearance or destruction of undesirable cells or noncellular molecular entities by tagging such cells or noncellular molecular entities with a marker that targets the cells or noncellular molecular entities for phagocytosis (phagocytic marker). The target cells can be, for example, endothelial cells, tumor cells, leukocytes, or virus-infected cells. In certain embodiments of the invention the tagging is accomplished by administering a composition comprising an antibody or ligand linked to the phagcytotic marker, wherein the antibody or ligand binds to a cell type specific marker present on or in the cell surface of a target cell. In preferred embodiments of the invention, the phagocytic marker comprises phosphatidylserine or a group derived from phosphatidylserine, thrombospondin-1, annexin I, or a derivative of any of these.
摘要翻译： 本发明提供了一种用于通过用靶向细胞或非细胞分子实体进行吞噬作用（吞噬标记）的标记来标记这样的细胞或非细胞分子实体来增强不需要的细胞或非细胞分子实体的清除或破坏的系统。 靶细胞可以是例如内皮细胞，肿瘤细胞，白细胞或病毒感染的细胞。 在本发明的某些实施方案中，标记通过施用包含与噬菌体标记物连接的抗体或配体的组合物来实现，其中所述抗体或配体结合存在于靶细胞的细胞表面上或细胞表面的细胞类型特异性标志物。 在本发明的优选实施方案中，吞噬标记物包含磷脂酰丝氨酸或衍生自磷脂酰丝氨酸，血小板反应素-1，膜联蛋白I或其任何衍生物的基团。
-
公开(公告)号：US20080075755A1
公开(公告)日：2008-03-27
申请号：US11612751
申请日：2006-12-19
申请人： Pascal Deschatelets , Paul Olson , Cedric Francois
发明人： Pascal Deschatelets , Paul Olson , Cedric Francois
CPC分类号： A61K38/162 , A61K9/0051 , A61K38/17
摘要： The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.
摘要翻译： 本发明提供用于治疗和/或预防年龄相关性黄斑变性和涉及黄斑变性或脉络膜新生血管形成，眼部炎症或其任何组合的其它病症的组合物和方法。 某些组合物包含痘病毒补体对照蛋白或其补体结合片段或变体。 其他组合物包含与结合存在于细胞或非细胞分子实体的表面或其表面上的组分连接的部分的痘病毒补体对照蛋白，例如存在于患有年龄相关性黄斑的风险的患者的眼睛中的组分 变性或相关病症或脉络膜新生血管形成，眼部炎症或这些的任何组合。 某些方法包括向受试者施用痘病毒补体对照蛋白或补体结合片段或其变体。
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.035 秒)
